SCHEDULE 13G: Vestal Point Capital Discloses 5.4% Stake in Tyra Biosciences
Beneficial Ownership Disclosure
Vestal Point Capital, LP and Ryan Wilder have disclosed a passive 5.4% beneficial ownership stake in Tyra Biosciences, Inc., holding 2,879,829 shares of common stock.
Summary
- Vestal Point Capital, LP, a Delaware limited partnership, and Ryan Wilder, its Chief Investment Officer and Managing Partner, have filed a Schedule 13G.
- The filing discloses beneficial ownership of 2,879,829 shares of common stock in Tyra Biosciences, Inc.
- This ownership represents 5.4% of Tyra Biosciences, Inc.'s outstanding common stock.
- The percentage is calculated based on 53,089,957 shares of common stock outstanding as of March 25, 2025, as reported in the Company's Annual Report on Form 10-K.
- Both reporting persons share voting and dispositive power over all 2,879,829 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, informing them of a new passive institutional investor.
Key Dates
| Date | Description |
|---|---|
| 03/25/2025 | Date as of which Tyra Biosciences, Inc. reported 53,089,957 shares of Common Stock outstanding in its Annual Report on Form 10-K. |
| 03/27/2025 | Date Tyra Biosciences, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/15/2025 | Date the Schedule 13G statement was signed and filed. |
Keywords
Tyra Biosciences, Vestal Point Capital, Ryan Wilder, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.